Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis

References

• SakkasLIBogdanosDPSystemic sclerosis: new evidence re-enforces the role of B cellsAutoimmun Rev201615215516126497107
   PubMed Web of Science ®Google Scholar
• O’ReillySCiechomskaMCantRHugleTvan LaarJMInterleukin-6, its role in fibrosing conditionsCytokine Growth Factor Rev20122339910722561547
   PubMed Web of Science ®Google Scholar
• CiechomskaMHuigensCAHugleTToll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factorsAnn Rheum Dis20137281382138923223421
   PubMed Web of Science ®Google Scholar
• KurasawaKHiroseKSanoHIncreased interleukin-17 in patients with systemic sclerosisArthritis Rheum200043112455246311083268
   PubMedGoogle Scholar
• SakkasLIPlatsoucasCDIs systemic sclerosis an antigen-driven T cell diseaseArthritis Rheum20045061721173315188347
   PubMedGoogle Scholar
• SakkasLIChikanzaICPlatsoucasCDMechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosisNat Clin Pract Rheumatol200621267968517133253
   PubMedGoogle Scholar
• RadstakeTRvan BonLBroenJThe pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and INFgamma distinguishes SSc phenotypesPLoS One200946e590319536281
   PubMed Web of Science ®Google Scholar
• OkamotoYHasagawaMMatsushitaTPotential roles of interleukin-17A in the development of skin fibrosis in miceArthritis Rheum201264113726373522833167
   PubMedGoogle Scholar
• Van BonLCossuMLoofAProteomic analysis of plasma identifies the toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phonotypeAnn Rheum Dis20147381585158924718960
   PubMed Web of Science ®Google Scholar
• YoshizakiAIwataYKomuraKCD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced sclerodermaAm J Pathol2008172616501663
   PubMed Web of Science ®Google Scholar
• YoshizakiATaniguchiTSaiqusaRNucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cellsAnn Rheum Dis Epub20151113
   PubMed Web of Science ®Google Scholar
• YorkMRNagaiTManginiAJLemaireRvan SeventerJMLafyatisRA macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonistsArthritis Rheum20075631010102017328080
   PubMed Web of Science ®Google Scholar
• TanakaTNarazakiMKishimotoTIL-6 in inflammation, immunity, and diseaseCold Spring Harb Perspect Biol2014610a01629525190079
   PubMed Web of Science ®Google Scholar
• SchellerJGarbersCRose-JohnSInterleukin-6: from basic biology to selective blockade of pro-inflammatory activitiesSemin Immunol201426121224325804
   PubMed Web of Science ®Google Scholar
• GarbersCAparicio-SieqmundSRose-JohnSThe IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibitionCurr Opin Immunol201534758225749511
   PubMed Web of Science ®Google Scholar
• RabeBChalarisAManUTransgenic blockade of interleukin 6 transsignaling abrogates inflammationBlood200811131021102817989316
   PubMed Web of Science ®Google Scholar
• HasegawaMSatoSFujimotoMIhnHKikuchiKTakeharaKSerum levels of interleukin 6(IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosisJ Rheumatol19982523083139489824
   PubMed Web of Science ®Google Scholar
• SatoSHasegawaMTakeharaKSerum levels of interleukin-6 and interlukin-10 correlate with total skin thickness score in patients with systemic sclerosisJ Dermatol Sci200127214014611532378
   PubMed Web of Science ®Google Scholar
• ScalaEPallottaSFrezzoliniACytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvementClin Exp Immunol2004138354054615544634
   PubMed Web of Science ®Google Scholar
• KhanKXuSNihtyanovaSClinical and pathological significance of interleukin 6 overexpression in systemic sclerosisAnn Rheum Dis20127171235124222586157
   PubMed Web of Science ®Google Scholar
• DesallaisLAvouacJFrechetMTargeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosisArthritis Res Ther2014164R157
   PubMed Web of Science ®Google Scholar
• De LauretisASestiniPPantelidisPSerum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosisJ Rheumatol20134043544623378460
   PubMed Web of Science ®Google Scholar
• FeghaliCABostKLBoulwareDWLevyLSControl of IL-6 expression and response in fibroblasts from patients with systemic sclerosisAutoimmunity19941743093187948613
   PubMed Web of Science ®Google Scholar
• MatsushitaTHasegawaMYanabaKKoderaMTakeharaKSatoSElevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytesArthritis Rheum200654119220116385515
   PubMed Web of Science ®Google Scholar
• KondoKOkadaTMatsuiTEstablishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblastsCytokine2001134320326
   Web of Science ®Google Scholar
• DuncanMRBermanBStimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6J Invest Dermatol19919746866921940439
   PubMed Web of Science ®Google Scholar
• O’ReillySCiechomskaMCantRvan LaarJMInterleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin proteinJ Biol Chem2014289149952996024550394
   PubMed Web of Science ®Google Scholar
• MauerJDensonJLBruningJCVersatile functions for IL-6 in metabolism and cancerTrends Immunol20153629210125616716
   PubMed Web of Science ®Google Scholar
• KitabaSMurotaHTeraoMBlockade of interleukin-6 receptor alleviates disease in mouse model of sclerodermaAm J Pathol2012180116517622062222
   PubMed Web of Science ®Google Scholar
• Le HuuDMatsushitaTJinGIL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host diseaseJ Invest Dermatol2012132122752276122810302
   PubMed Web of Science ®Google Scholar
• SteinerMKSyrkinaOLKolliputiNMarkEJHalesCAWaxmanABInterleukin-6 overexpression induces pulmonary hypertensionCirc Res2009104223624419074475
   PubMed Web of Science ®Google Scholar
• SavaleLTuLRideauDImpact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in miceRespir Res200910619173740
   PubMed Web of Science ®Google Scholar
• SatoKTsuchiyaMSaldanhaJReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growthCancer Res19935348518568428365
   PubMed Web of Science ®Google Scholar
• ShirotaYYarboroCFischerRPhamTHLipskyPIlleiGGImpact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosusAnn Rheum Dis20137211812822858586
   PubMed Web of Science ®Google Scholar
• RollPMuhammadKSchumannMIn vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartmentArthritis Rheum2011631255126421305508
   PubMed Web of Science ®Google Scholar
• SnirAKesselAHajTRosnerISlobodinGToubiEAnti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapyClin Exp Rheumatol20112969770021813064
   PubMed Web of Science ®Google Scholar
• ShettyAHansonRKorstenPTocilizumab in the treatment of rheumatoid arthritis and beyondDrug Des Devel Ther20148349364
   PubMed Web of Science ®Google Scholar
• NishimotoNTeraoKMimaTNakaharaHTakagiNKakehiTMechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood2008112103959396418784373
   PubMed Web of Science ®Google Scholar
• Kowal-BieleckaOLandeweRAvouacJEULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)Ann Rheum Dis200968562062819147617
   PubMed Web of Science ®Google Scholar
• van LaarJMFargeDSontJKAutologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trialJAMA2014311242490249825058083
   PubMed Web of Science ®Google Scholar
• OmairMAAlahmadiAJohnsonSRSafety and effectiveness of mycophenolate in systemic sclerosis. A systematic reviewPLoS One2015105e012420525933090
   PubMed Web of Science ®Google Scholar
• GiuggioliDLumettiFColaciMFallahiPAntonelliAFerriCRituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literatureAutoimmun Rev201514111072107826209905
   PubMed Web of Science ®Google Scholar
• BarrTAShenPBrownSB cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cellsJ Exp Med201220951001101022547654
   PubMed Web of Science ®Google Scholar
• DasSVitalEMHortonSAbatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapyAnn Rheum Dis201473590991224385201
   PubMed Web of Science ®Google Scholar
• WalkerUAJaegerVKChatzidionysiouKRituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritisRheumatology (Oxford)201655223023626316581
   PubMed Web of Science ®Google Scholar
• KondoMMurakawaYMatsumuraTA case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?Rheumatology (Oxford)201453101907190824859996
   PubMed Web of Science ®Google Scholar
• SaitoESatoSNogiSA case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with tocilizumab for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosisCase Rep Rheumatol2014201438632824839573
   PubMedGoogle Scholar
• ShimaYKuwaharaYMurotaHThe skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumabRheumatology (Oxford)201049122408241220819796
   PubMed Web of Science ®Google Scholar
• ElhaiMMeunierMMatucci-CerinicMOutcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational studyAnn Rheum Dis20137271217122023253926
   PubMed Web of Science ®Google Scholar
• Fernandes das NevesMOliveiraSAmaralMCDelgado AlvesJTreatment of systemic sclerosis with tocilizumabRheumatology (Oxford)201554237137225480809
   PubMed Web of Science ®Google Scholar
• ShimaYHosenNHiranoTExpansion of range of joint motion following treatment of systemic sclerosis with tocilizumabMod Rheumatol201525113413724533556
   PubMed Web of Science ®Google Scholar
• FrechTMHudsonMProtective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literatureClin Exp Rheumatol2015334 Suppl 91S179S18126339896
   PubMed Web of Science ®Google Scholar
• KhannaDDentonCPJahreisASafety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialLancet Epub201655
   Web of Science ®Google Scholar
• KuhnKAManieriNALiuTCStappenbeckTSIL-6 stimulates intestinal epithelial cell proliferation and repair after injuryPLoS One20149e11419525478789
   PubMed Web of Science ®Google Scholar